Loading
Life sciences · Journal article
Future Oncology · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
For patients with estrogen receptor-positive (ER+)/HER2-negative (HER2-) advanced breast cancer (aBC), endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i) is standard first-line treatment. However, ET resistance eventually develops, leading to disease progression. Mechanisms of endocrine resistance include PI3K/AKT/mTOR pathway constitutive activation and acquired mutations in the estrogen receptor 1 (ESR1) gene. Novel approaches are needed to improve outcomes for patients progressing on ET plus CDK4/6i. Elacestrant, a next-generation oral selective estrogen receptor degrader, is approved for patients with ER+/HER2- ESR1-mutated aBC after at least one line of ET, including a CDK4/6i. Everolimus, an mTORC1 inhibitor, is indicated in combination with exemestane for the treatment of postmenopausal women with ER+/HER2- aBC after progression on non-steroidal aromatase inhibitors. In the ELEVATE phase Ib/II trial, elacestrant plus everolimus showed a clinically meaningful progression-free survival (PFS) irrespective of ESR1 or PIK3CA mutation status in patients with ER+/HER2- aBC progressing after ET plus CDK4/6i. Here, we describe the design and methodology of ADELA, an international, multicenter, double-blind, placebo-controlled, randomized phase III trial evaluating elacestrant plus everolimus versus elacestrant plus placebo in patients with ER+/HER2-, ESR1-mutated aBC following ET plus CDK4/6i. The primary endpoint is PFS assessed by a blinded imaging review committee using RECIST v.1.1.Clinical trial registration www.clinicaltrials.gov identifier is NCT06382948; EU Clinical Trials identifier is EUCT 2024-512926-27-00.